Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Parathyroid Hyperplasia
• MONDO ID: (if available)
• Category: Complex

Research Objectives

Please provide a comprehensive research report on Parathyroid Hyperplasia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Parathyroid Hyperplasia

Target disease

Disease name: Parathyroid hyperplasia (clinical entity spanning PHPT-associated multigland disease; CKD-related secondary hyperplasia; autonomous tertiary disease) (jha2023molecularandclinical pages 8-9, vetter2024whatisthe pages 1-3, costea2025tertiaryhyperparathyroidismin pages 4-6)
Category: Complex (etiologies include sporadic, hereditary, and CKD-driven mineral-bone disorder) (jha2023molecularandclinical pages 8-9, vetter2024whatisthe pages 1-3)

MONDO / ontology note

A specific MONDO identifier for the standalone label “parathyroid hyperplasia” was not retrieved in the current full-text corpus. However, MONDO identifiers are available for closely related entities used in practice (e.g., hereditary hyperparathyroidism MONDO_0016166) via Open Targets (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET). This report therefore uses ontology annotations at the phenotype/mechanism/action level (HPO/GO/UBERON/MAXO) plus gene/syndrome identifiers for hereditary forms.

1. Disease information

1.1 Concise overview (current clinical understanding)

“Parathyroid hyperplasia” refers to enlargement/proliferation of parathyroid tissue and is used in different ways depending on clinical context:
Primary hyperparathyroidism (PHPT) context: multigland involvement historically called “hyperplasia,” now often termed multiglandular parathyroid disease (MGD) in WHO 2022 terminology; clinically defined by >1 abnormal gland rather than a histologic gold standard (jha2023molecularandclinical pages 8-9, chakrabarty2024imagingrecommendationsfor pages 3-5).
Secondary hyperparathyroidism (SHPT) context: CKD-driven compensatory hyperplasia due to chronic disturbances in phosphate/calcitriol/calcium homeostasis (vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2).
Tertiary hyperparathyroidism (tHPT) context:* autonomous hyperparathyroidism after prolonged SHPT (often post-transplant), typically multiglandular (vetter2024whatisthe pages 10-12, costea2025tertiaryhyperparathyroidismin pages 4-6).

Direct abstract-supported statement (PHPT): a 2024 review summarizes causes/relative proportions and states that in PHPT, solitary adenoma is ~80–85% and multiglandular disease is ~10–15% (chakrabarty2024imagingrecommendationsfor pages 1-2).

1.2 Key identifiers (retrieved in corpus)

• MONDO (related): hereditary hyperparathyroidism MONDO_0016166 (Open Targets) (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET).
• ClinicalTrials.gov: NCT03027557 (DENOCINA trial in PHPT) (NCT03027557 chunk 1, NCT03027557 chunk 3); NCT01421407 (HIFU for SHPT; withdrawn, 0 enrollment) (NCT01421407 chunk 1).

Not retrievable from the current corpus: ICD-10/ICD-11 codes, MeSH IDs, and Orphanet IDs specifically for “parathyroid hyperplasia.”

1.3 Synonyms / alternative names

• Multiglandular parathyroid disease (MGD) (preferred term in PHPT setting per WHO 2022 updates) (chakrabarty2024imagingrecommendationsfor pages 3-5).
• “Four-gland hyperplasia,” “diffuse hyperplasia” (common in surgical series/management discussions) (pavlidis2023updateonthe pages 1-2).
• Renal/CKD-associated “parathyroid hyperplasia” in SHPT (vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2).

1.4 Evidence source types represented here

• Aggregated disease-level resources: major reviews and systematic reviews (Endocrine Reviews 2023; genetics review 2024; imaging review 2024; MRI systematic review 2023) (jha2023molecularandclinical pages 7-8, english2024geneticsofhereditary pages 8-9, chakrabarty2024imagingrecommendationsfor pages 1-2, scheepers2023diagnosticperformanceof pages 13-14).
• Human clinical cohorts: atypical parathyroid adenoma/carcinoma comparative cohort with complication frequencies (Frontiers Endocrinology 2023) (chen2023clinicalandgenetic pages 1-2, chen2023clinicalandgenetic pages 6-8).
• Clinical trials registry records: NCT03027557; NCT01421407 (NCT03027557 chunk 1, NCT01421407 chunk 1).
• Human molecular profiling: transcriptome/miRNA/lncRNA profiling of sporadic parathyroid adenomas (2024) (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).

2. Etiology

2.1 Disease causal factors

A) PHPT-associated multigland disease (“primary hyperplasia” / MGD)

PHPT is defined as inappropriate excess PTH relative to calcium due to intrinsic parathyroid pathology; etiologies include single adenoma, MGD (hyperplasia/double adenomas), and carcinoma (jha2023molecularandclinical pages 8-9, chakrabarty2024imagingrecommendationsfor pages 1-2). In PHPT, MGD is enriched in hereditary cases (jha2023molecularandclinical pages 8-9, jha2023molecularandclinical pages 1-2).

B) CKD-related SHPT (“secondary hyperplasia”)

Secondary hyperparathyroidism in CKD arises from disturbed mineral metabolism: early CKD features increased FGF-23 with reduced activated vitamin D; progressive CKD yields hyperphosphatemia, reduced activated vitamin D, hypocalcemia, and compensatory parathyroid hyperplasia (hiramitsu2023treatmentforsecondary pages 1-2). A 2024 surgical review explicitly links chronic hypocalcemia, hyperphosphatemia, and low calcitriol to parathyroid hyperplasia (vetter2024whatisthe pages 1-3).

C) Autonomous tertiary hyperparathyroidism (tHPT)

A 2024 review describes the mechanistic progression: prolonged SHPT stimulation can cause nodular remodeling, reduced calcium-sensing/vitamin-D receptor sensitivity, and autonomy; this is the conceptual basis for tertiary HPT, often after kidney transplantation (vetter2024whatisthe pages 1-3). A narrative review defines tertiary HPT as “autonomous parathyroid gland function, hypercalcemia, and progressive enlargement of all four parathyroid glands” (costea2025tertiaryhyperparathyroidismin pages 4-6).

2.2 Risk factors

Genetic (hereditary PHPT / multigland disease)

Hereditary forms are clinically important because they are often multiglandular and change operative strategy and family management. Direct abstract-supported statement: “Approximately 15% of patients with PHPT have an underlying heritable form” (jha2023molecularandclinical pages 1-2). A 2024 review states hereditary forms account for >10% of PHPT and provides penetrance estimates for syndromes (english2024geneticsofhereditary pages 1-2).

Key hereditary genes/syndromes include MEN1, CDC73 (HPT-JT), RET (MEN2A), CDKN1B (MEN4), CASR/GNA11/AP2S1 (FHH1–3 differential), and GCM2 (FIHP) (jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24, english2024geneticsofhereditary pages 1-2). In one selected high-risk cohort, germline variants were identified in 28.2% (11/39), comprising MEN1 (17.9%) and CDC73 (10.2%) (preprint; interpret cautiously) (qadir2024moleculargeneticsin pages 1-3).

Environmental/iatrogenic and clinical risk factors

• In PHPT, causes may include sporadic disease and associations such as prior radiation exposure or sarcoidosis in some settings (review-level statements) (chakrabarty2024imagingrecommendationsfor pages 1-2).
• For persistence/recurrence after PHPT surgery (a practical “risk factor” for adverse outcome), multigland hyperplasia/double adenomas carry higher risk (pavlidis2023updateonthe pages 1-2).

2.3 Protective factors

The retrieved corpus does not provide validated “protective factors” (genetic or environmental) that reduce risk of developing parathyroid hyperplasia. However, appropriate CKD-mineral bone disorder management (phosphate control, vitamin D correction) is mechanistically protective against SHPT progression (vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2).

2.4 Gene–environment interactions

Direct gene–environment interaction studies specific to “parathyroid hyperplasia” were not retrieved in the current corpus. Clinically, gene-driven multigland PHPT (e.g., MEN1) and environment/organ-disease-driven SHPT (CKD) represent distinct but sometimes overlapping pathways to gland enlargement (english2024geneticsofhereditary pages 1-2, vetter2024whatisthe pages 1-3).

3. Phenotypes

Major phenotypes and suggested HPO mappings are summarized in the phenotype table below.

Table: This table maps major clinical and laboratory phenotypes relevant to parathyroid hyperplasia and hyperparathyroidism to suggested HPO terms, with recent quantitative data where available. It is useful for structuring phenotype annotations in a disease knowledge base.

3.1 Clinical phenotype highlights with recent quantitative data

• Bone involvement is common in hyperparathyroid states. In a 2023 cohort comparing atypical parathyroid adenoma (APA) vs carcinoma, bone involvement was 35.4% in APA vs 62.0% in carcinoma (chen2023clinicalandgenetic pages 1-2).
• Renal calcification/nephrolithiasis is frequent: urolithiasis was 57.0% in APA vs 29.6% in benign lesions (chen2023clinicalandgenetic pages 1-2), and nephrolithiasis/renal calcification frequencies were reported up to 87.5% in one APA subgroup (chen2023clinicalandgenetic pages 6-8).
• Systemic symptoms / fatigue are reported in advanced hyperparathyroid disease: fatigue frequency 13.6% in a carcinoma systematic review subset (roser2023diagnosisandmanagement pages 3-5).

3.2 Quality-of-life impact

A 2023 SHPT surgical review states parathyroidectomy is associated with improved quality of life (alongside improved bone density, fracture risk, and survival) (hiramitsu2023treatmentforsecondary pages 1-2). Quantitative QoL instrument scores (e.g., SF-36/EQ-5D) were not present in the retrieved corpus.

4. Genetic / molecular information

4.1 Causal genes (human hereditary PHPT and differential diagnoses)

Key hereditary genes are summarized here and in the genetics table:

Table: This table summarizes the main hereditary genes linked to parathyroid hyperplasia, multiglandular disease, or closely related hereditary PHPT phenotypes. It highlights inheritance, the usual parathyroid pattern, and key statistics that help distinguish true multigland disease from mimics such as familial hypocalciuric hypercalcemia.

Notable gene-level points (selected): * MEN1 is the most common syndromic cause of hereditary PHPT; sporadic tumors also frequently show somatic MEN1 alterations (review summaries) (english2024geneticsofhereditary pages 1-2, simonds2020clinicalandmolecular pages 3-4).
CDC73 (HPT-JT) confers clinically important carcinoma risk (reported ~20–25% in a 2023 review summary) and needs long-term surveillance approaches in carriers (jha2023molecularandclinical pages 15-16, simonds2020clinicalandmolecular pages 4-6).
CASR/GNA11/AP2S1 mutations cause familial hypocalciuric hypercalcemia (FHH), which mimics PHPT but is usually not corrected by parathyroidectomy (jha2023molecularandclinical pages 15-16, jha2023molecularandclinical pages 23-24).

4.2 Pathogenic variants / variant types

The retrieved corpus did not provide a comprehensive ClinVar-style variant catalog for parathyroid hyperplasia. However, one 2024 cohort report lists multiple MEN1 and CDC73 variants detected by NGS panel in a selected high-risk set (qadir2024moleculargeneticsin pages 1-3). For knowledge base entry, variant-level data should be completed by targeted ClinVar/HGMD extraction.

4.3 Epigenetics and regulatory mechanisms

A 2023 Endocrine Reviews synthesis notes that reduced CASR expression is common in sporadic PHPT tumors and may be driven by epigenetic deregulation (hypermethylation and histone modifications) and altered upstream regulators (jha2023molecularandclinical pages 11-12). The same review highlights broad epigenetic alterations and noncoding RNA regulation as potentially reversible contributors (jha2023molecularandclinical pages 11-12).

4.4 Recent omics: 2024 transcriptome/lncRNA profiling

A 2024 study profiled 32 sporadic parathyroid adenomas with gene, microRNA, and lncRNA expression, clustering tumors by a MEN1/CDC73/GCM2/CASR/VDR/CCND1/CDKN1B gene set; CDC73 and CDKN1B expression drove clustering, and distinct lncRNA patterns were associated with biochemical severity differences (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2, verdelli2024heterogeneoustranscriptionallandscapes pages 7-9). This provides a current example of molecular heterogeneity relevant to understanding why some tumors behave more “quiescent” vs “severe” clinically (verdelli2024heterogeneoustranscriptionallandscapes pages 7-9).

5. Environmental information

The dominant “environmental” drivers in the retrieved corpus are organ-disease mediated exposures, especially CKD-related mineral and endocrine disturbance: * CKD-related drivers: hyperphosphatemia, calcitriol deficiency, hypocalcemia, elevated FGF23, and related inflammatory/oxidative mechanisms contribute to hyperplasia and SHPT progression (hiramitsu2023treatmentforsecondary pages 1-2, costea2025tertiaryhyperparathyroidismin pages 2-4).
* No infectious triggers were identified in the retrieved corpus.

6. Mechanism / pathophysiology

6.1 Causal chain (representative)

SHPT (CKD) → hyperplasia → autonomy (tHPT)

1. CKD causes phosphate retention, increased FGF23, reduced activated vitamin D, and hypocalcemia (hiramitsu2023treatmentforsecondary pages 1-2).
2. Chronic hypocalcemia/hyperphosphatemia/low calcitriol stimulate parathyroid gland growth → diffuse hyperplasia (vetter2024whatisthe pages 1-3).
3. Over time, nodular remodeling and decreased VDR/CaSR sensitivity emerge; somatic changes may shift to monoclonal proliferation, contributing to autonomy and refractoriness (tHPT) (vetter2024whatisthe pages 1-3).
4. tHPT manifests as persistent high PTH with hypercalcemia and multigland enlargement, often requiring surgical management (costea2025tertiaryhyperparathyroidismin pages 4-6, vetter2024whatisthe pages 10-12).

PHPT multigland disease (MGD)

PHPT MGD reflects intrinsic multi-gland pathology (often genetic susceptibility-driven) and is described clinically by multiple abnormal glands; WHO 2022 favors MGD terminology and notes limited histologic discriminability between adenoma vs hyperplasia in practice (jha2023molecularandclinical pages 8-9, chakrabarty2024imagingrecommendationsfor pages 3-5).

6.2 Key molecular pathways and processes

• Calcium sensing / CaSR signaling: CaSR is central to chief-cell sensing of ionized calcium and PTH regulation; reviews note that many sporadic tumors show reduced CASR expression and that Casr loss models cause severe hyperparathyroidism (simonds2020clinicalandmolecular pages 1-3, jha2023molecularandclinical pages 11-12).
• Vitamin D receptor (VDR) signaling: SHPT progression involves decreased VDR expression in nodular hyperplasia; VDRAs are core therapies (hiramitsu2023treatmentforsecondary pages 1-2, sevva2024pharmaceuticalmanagementof pages 2-3).
• Tumor suppressor pathways: MEN1/CDC73 biology shapes hereditary and sporadic tumorigenesis and is a key part of modern molecular classification (jha2023molecularandclinical pages 10-11, verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).
• Epigenetic and noncoding RNA regulation: DNA methylation/histone modification and miRNA/lncRNA changes (e.g., C19MC, NEAT1, HOXA-AS RNAs) are implicated in heterogeneity and tumor biology (jha2023molecularandclinical pages 11-12, verdelli2024heterogeneoustranscriptionallandscapes pages 7-9).

6.3 Suggested ontology terms

• GO biological processes (examples): regulation of hormone secretion; calcium ion homeostasis; regulation of cell population proliferation; epigenetic regulation of gene expression (supported mechanistically by CaSR/VDR signaling and epigenetic findings) (jha2023molecularandclinical pages 11-12, verdelli2024heterogeneoustranscriptionallandscapes pages 7-9).
• Cell Ontology (CL) (examples): parathyroid chief cell (primary endocrine cell type producing PTH; referenced mechanistically in PHPT) (simonds2020clinicalandmolecular pages 1-3).
• CHEBI examples: calcium(2+) and phosphate as key ions driving biochemical phenotype (implied by CKD/PHPT mineral metabolism discussions) (hiramitsu2023treatmentforsecondary pages 1-2, vetter2024whatisthe pages 1-3).

7. Anatomical structures affected

7.1 Primary organ

• Parathyroid gland (UBERON:0001132) — diffuse hyperplasia or multigland neoplasia (PHPT-MGD, SHPT, tHPT) (vetter2024whatisthe pages 1-3, jha2023molecularandclinical pages 8-9).

7.2 Major secondary organ systems (complications)

• Skeletal system / bone (e.g., cortical bone loss, fractures, renal osteodystrophy): frequent and clinically significant (jha2023molecularandclinical pages 7-8, chen2023clinicalandgenetic pages 1-2).
• Kidney / urinary tract (nephrolithiasis, nephrocalcinosis, renal failure/CKD): frequent and clinically significant (jha2023molecularandclinical pages 7-8, roser2023diagnosisandmanagement pages 3-5).
• Cardiovascular system (particularly in CKD-related SHPT/tHPT; broader morbidity links): noted in SHPT/tHPT overviews (vetter2024whatisthe pages 1-3, hiramitsu2023treatmentforsecondary pages 1-2).

7.3 Subcellular/localization (mechanistic)

• Plasma membrane: CaSR localization is central to extracellular calcium sensing (simonds2020clinicalandmolecular pages 1-3).
• Nucleus/chromatin: epigenetic regulation (histone marks H3K4/H3K27) implicated via lncRNA–histone interactions and menin/parafibromin biology (verdelli2024heterogeneoustranscriptionallandscapes pages 7-9, verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).

8. Temporal development

• PHPT MGD may present earlier in hereditary disease compared with sporadic single-adenoma disease; genetic testing is recommended in young onset (≤40), recurrent disease, or multigland disease (jha2023molecularandclinical pages 1-2).
• SHPT typically evolves with CKD progression and can advance to nodular hyperplasia (hiramitsu2023treatmentforsecondary pages 1-2).
• tHPT occurs after prolonged SHPT; persistent post-transplant hyperparathyroidism remains common, with reported rates declining from ~70% at 1 year to ~43% at 2 years after transplantation in cited series (vetter2024whatisthe pages 1-3).

9. Inheritance and population

9.1 Epidemiology (PHPT as the major primary context)

A 2023 Endocrine Reviews article provides sex-stratified incidence estimates for PHPT: ~66 per 100,000 person-years in women and ~25 per 100,000 in men (jha2023molecularandclinical pages 7-8). It also reports that PHPT is associated with fractures, kidney stones, CKD, and increased mortality (jha2023molecularandclinical pages 7-8).

9.2 Heritable fraction and penetrance

• Heritable PHPT fraction: “Approximately 15%” in one 2023 synthesis (jha2023molecularandclinical pages 1-2).
• Penetrance examples from a 2024 genetics review: MEN1 PHPT ~90% by age 70; MEN2 ~5–15%; MEN4 ~75%; HPT-JT ~95% (review summary table) (english2024geneticsofhereditary pages 1-2).

10. Diagnostics

10.1 Diagnostic workup summary (labs + imaging)

Table: This table summarizes the current diagnostic workup for parathyroid hyperplasia and related hyperparathyroid states, including key laboratory tests, localization imaging, intraoperative monitoring, and special considerations for multigland disease and CKD-related secondary/tertiary hyperparathyroidism.

Key recent imaging developments relevant to “hyperplasia” (MGD):
MRI systematic review (Dec 2023): conventional MRI sensitivity 39.1–94.3%; 4D MRI 55.6–100%; PET/MRI (18F-FCH) 84.2–100% (scheepers2023diagnosticperformanceof pages 13-14, scheepers2023diagnosticperformanceof pages 9-11). In MGD specifically, reported MRI sensitivities 67–100%, versus MIBI ~44% and 4DCT ~60% in cited comparisons (scheepers2023diagnosticperformanceof pages 14-15).
2024 imaging review: provides a dedicated management branch for MGD (formerly hyperplasia) recommending imaging for planning and then bilateral neck exploration with subtotal/total parathyroidectomy (algorithm figure) (chakrabarty2024imagingrecommendationsfor media a62b0df1). The same source includes a summary table of imaging modalities (advantages/limitations) (chakrabarty2024imagingrecommendationsfor media 9629bfff).

10.2 Key differential diagnosis: familial hypocalciuric hypercalcemia (FHH)

A 2024 genetics review recommends urinary calcium-to-creatinine clearance ratio (UCCR) testing; most FHH cases have UCCR < 0.01, supporting distinction from PHPT/MGD and preventing unnecessary surgery (english2024geneticsofhereditary pages 1-2).

10.3 Genetics in diagnosis

Genetic testing is recommended for individuals with multigland disease, recurrent PHPT, young onset, or family history (jha2023molecularandclinical pages 1-2). A 2024 genetics review similarly recommends testing when hereditary PHPT is suspected (e.g., young age, multigland/hyperplasia, carcinoma, known familial mutation) because results guide surgery and surveillance (english2024geneticsofhereditary pages 8-9, english2024geneticsofhereditary pages 1-2).

11. Outcome / prognosis

11.1 Persistence/recurrence after PHPT surgery

A 2023 surgical-management review reports recurrence after parathyroidectomy historically 4–10%, decreasing to 2.5–5% with modern advances; hyperplasia/MGD is a risk factor for persistence/recurrence (pavlidis2023updateonthe pages 1-2). It provides pragmatic thresholds: intraoperative PTH ≤40 pg/mL or ≥50% drop predicts low persistence risk; and at 6 months, calcium ≥9.8 mg/dL and PTH ≥80 pg/mL indicate recurrence risk (pavlidis2023updateonthe pages 1-2).

11.2 Renal/transplant outcomes in tHPT

A 2024 transplant-focused surgical review reports that (in cited retrospective comparisons) parathyroidectomy produced higher PTH normalization and lower kidney allograft loss versus cinacalcet (9% vs 33% graft failure) (vetter2024whatisthe pages 10-12).

12. Treatment

Table: This table summarizes treatment strategies and real-world implementation of therapies for parathyroid hyperplasia across primary multigland disease, CKD-related secondary hyperparathyroidism, and post-transplant tertiary hyperparathyroidism. It highlights surgical standards, medical therapies, response statistics, and relevant clinical trial identifiers.

12.1 PHPT multigland disease (MGD)

• Standard approach is surgical exploration (bilateral neck exploration) and subtotal or total parathyroidectomy, consistent with modern imaging-guided algorithms (chakrabarty2024imagingrecommendationsfor media a62b0df1).
• Intraoperative PTH monitoring criteria are used to reduce persistence risk in PHPT surgery (pavlidis2023updateonthe pages 1-2).

12.2 SHPT (CKD-related hyperplasia)

• Medical therapy: phosphate control, VDRAs, and calcimimetics (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3).
• Real-world implementation (2018–2023 cohort): IV etelcalcetide during dialysis reduced PTH in 29/33 (87.9%) patients, up to 57% reduction from baseline, with no parathyroidectomies required in that series (sevva2024pharmaceuticalmanagementof pages 1-2).
• Surgery: parathyroidectomy remains key for drug-refractory disease; a 2023 review emphasizes that for SHPT, complete removal of all glands is needed to avoid persistence/recurrence and notes improved bone density, fracture risk, survival, and QoL after surgery (hiramitsu2023treatmentforsecondary pages 1-2).

12.3 tHPT (autonomous, often post-transplant)

A 2024 review emphasizes multigland disease (~90%) and generally favors subtotal parathyroidectomy with four-gland exploration (vetter2024whatisthe pages 10-12).

12.4 Experimental/procedural

• HIFU for SHPT: NCT01421407 planned an endpoint of ≥30% iPTH reduction at 6 months but was withdrawn with 0 enrollment (NCT01421407 chunk 1).
• PHPT medical therapy trial: NCT03027557 (DENOCINA) tested denosumab and cinacalcet regimens in PHPT (NCT03027557 chunk 1, NCT03027557 chunk 3).

12.5 Suggested MAXO terms (examples)

• Parathyroidectomy (MAXO:0000004) (supported clinically across PHPT-MGD, SHPT, tHPT) (chakrabarty2024imagingrecommendationsfor media a62b0df1, hiramitsu2023treatmentforsecondary pages 1-2, vetter2024whatisthe pages 10-12).
• Treatment with calcimimetic (e.g., cinacalcet/etelcalcetide) (MAXO term to be selected in downstream curation) (sevva2024pharmaceuticalmanagementof pages 1-2, sevva2024pharmaceuticalmanagementof pages 2-3).
• Vitamin D supplementation/therapy (VDRAs) (MAXO curation candidate) (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3).

13. Prevention

• Primary/secondary prevention for SHPT progression (CKD): dietary phosphate restriction and phosphate binders plus vitamin D/VDRAs to reduce chronic parathyroid stimulation are standard mechanistic approaches (vetter2024whatisthe pages 1-3, sevva2024pharmaceuticalmanagementof pages 2-3).
• Secondary prevention for hereditary PHPT/MGD: genetic testing when indicated and cascade testing in relatives can enable earlier detection and tailored surveillance/surgical planning (english2024geneticsofhereditary pages 1-2, jha2023molecularandclinical pages 1-2).
• Postoperative secondary prevention: vitamin D status is emphasized as a factor for good outcomes after PHPT surgery and is routinely assessed and corrected (pavlidis2023updateonthe pages 1-2).

14. Other species / natural disease

No naturally occurring non-human species datasets for “parathyroid hyperplasia” were retrieved in the current corpus.

15. Model organisms

Direct primary model-organism papers were not retrieved as full text in the current corpus; however, authoritative reviews cite several mechanistic models relevant to hyperplasia/tumorigenesis: * Parathyroid-specific Casr loss → severe hyperparathyroidism (jha2023molecularandclinical pages 11-12).
MEN1 loss → parathyroid hyperplasia/adenomas (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).
CDC73 deletion → tumor formation (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).
CDKN1B (p27)* loss → adenoma predisposition (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2).

Key structured summaries for knowledge-base ingestion

The following tables consolidate the most actionable structured content.

Clinical classification and definitions

Table: This table summarizes the main clinical classifications of parathyroid hyperplasia and related multigland disease, contrasting primary PHPT-associated MGD with CKD-related secondary hyperplasia and autonomous tertiary disease. It also highlights the WHO 2022 terminology shift toward 'multiglandular parathyroid disease' in PHPT.

Genetics (syndromes, inheritance, patterns)

Table: This table summarizes the main hereditary genes linked to parathyroid hyperplasia, multiglandular disease, or closely related hereditary PHPT phenotypes. It highlights inheritance, the usual parathyroid pattern, and key statistics that help distinguish true multigland disease from mimics such as familial hypocalciuric hypercalcemia.

Diagnostics (labs, imaging, performance statistics)

Table: This table summarizes the current diagnostic workup for parathyroid hyperplasia and related hyperparathyroid states, including key laboratory tests, localization imaging, intraoperative monitoring, and special considerations for multigland disease and CKD-related secondary/tertiary hyperparathyroidism.

Treatments and real-world implementation

Table: This table summarizes treatment strategies and real-world implementation of therapies for parathyroid hyperplasia across primary multigland disease, CKD-related secondary hyperparathyroidism, and post-transplant tertiary hyperparathyroidism. It highlights surgical standards, medical therapies, response statistics, and relevant clinical trial identifiers.

Visual evidence (imaging review)

The 2024 imaging review contains (i) a table comparing imaging modalities and (ii) a management algorithm with a dedicated multigland disease branch supporting bilateral neck exploration with subtotal/total parathyroidectomy (chakrabarty2024imagingrecommendationsfor media 9629bfff, chakrabarty2024imagingrecommendationsfor media a62b0df1).

Limitations of this synthesis

• ICD/MeSH/Orphanet/MONDO identifiers specific to “parathyroid hyperplasia” were not available in the retrieved full texts; ontology anchoring is therefore provided via related MONDO entities, gene syndromes, and HPO/GO/UBERON mappings.
• Several key areas (variant cataloging with allele frequencies; standardized QoL instruments; dedicated SHPT/tHPT RCTs beyond trial registry records) require targeted database retrieval beyond the current evidence set.

References

1. (jha2023molecularandclinical pages 8-9): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.

2. (vetter2024whatisthe pages 1-3): Diana Vetter and Thomas Schachtner. What is the role of surgery in secondary and tertiary hyperparathyroidism? Advances in Kidney Transplantation [Working Title], Aug 2024. URL: https://doi.org/10.5772/intechopen.1006528, doi:10.5772/intechopen.1006528. This article has 0 citations.

3. (costea2025tertiaryhyperparathyroidismin pages 4-6): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.

4. (OpenTargets Search: Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET): Open Targets Query (Hyperparathyroidism,Secondary hyperparathyroidism,Primary hyperparathyroidism-CASR,PTH,GCM2,MEN1,CDC73,RET, 37 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (chakrabarty2024imagingrecommendationsfor pages 3-5): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.

6. (hiramitsu2023treatmentforsecondary pages 1-2): Takahisa Hiramitsu, Yuki Hasegawa, Kenta Futamura, Manabu Okada, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai, Yoshihiro Tominaga, and Toshihiro Ichimori. Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Frontiers in Endocrinology, Apr 2023. URL: https://doi.org/10.3389/fendo.2023.1169793, doi:10.3389/fendo.2023.1169793. This article has 47 citations.

7. (vetter2024whatisthe pages 10-12): Diana Vetter and Thomas Schachtner. What is the role of surgery in secondary and tertiary hyperparathyroidism? Advances in Kidney Transplantation [Working Title], Aug 2024. URL: https://doi.org/10.5772/intechopen.1006528, doi:10.5772/intechopen.1006528. This article has 0 citations.

8. (chakrabarty2024imagingrecommendationsfor pages 1-2): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.

9. (NCT03027557 chunk 1): Peter Vestergaard. Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.. Peter Vestergaard. 2017. ClinicalTrials.gov Identifier: NCT03027557

10. (NCT03027557 chunk 3): Peter Vestergaard. Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.. Peter Vestergaard. 2017. ClinicalTrials.gov Identifier: NCT03027557

11. (NCT01421407 chunk 1): Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism. Theraclion. 2011. ClinicalTrials.gov Identifier: NCT01421407

12. (pavlidis2023updateonthe pages 1-2): Efstathios T Pavlidis and Theodoros E Pavlidis. Update on the current management of persistent and recurrent primary hyperparathyroidism after parathyroidectomy. World Journal of Clinical Cases, 11:2213-2225, Apr 2023. URL: https://doi.org/10.12998/wjcc.v11.i10.2213, doi:10.12998/wjcc.v11.i10.2213. This article has 23 citations.

13. (jha2023molecularandclinical pages 7-8): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.

14. (english2024geneticsofhereditary pages 8-9): Katherine A. English, Kate E. Lines, and Rajesh V. Thakker. Genetics of hereditary forms of primary hyperparathyroidism. Hormones (Athens, Greece), 23:3-14, Dec 2024. URL: https://doi.org/10.1007/s42000-023-00508-9, doi:10.1007/s42000-023-00508-9. This article has 41 citations.

15. (scheepers2023diagnosticperformanceof pages 13-14): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.

16. (chen2023clinicalandgenetic pages 1-2): Yingyu Chen, An Song, Min Nie, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, and Xiaoping Xing. Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a chinese cohort. Frontiers in Endocrinology, Jan 2023. URL: https://doi.org/10.3389/fendo.2023.1027598, doi:10.3389/fendo.2023.1027598. This article has 19 citations.

17. (chen2023clinicalandgenetic pages 6-8): Yingyu Chen, An Song, Min Nie, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, and Xiaoping Xing. Clinical and genetic analysis of atypical parathyroid adenoma compared with parathyroid carcinoma and benign lesions in a chinese cohort. Frontiers in Endocrinology, Jan 2023. URL: https://doi.org/10.3389/fendo.2023.1027598, doi:10.3389/fendo.2023.1027598. This article has 19 citations.

18. (verdelli2024heterogeneoustranscriptionallandscapes pages 1-2): Chiara Verdelli, Silvia Carrara, Riccardo Maggiore, Paolo Dalino Ciaramella, and Sabrina Corbetta. Heterogeneous transcriptional landscapes in human sporadic parathyroid gland tumors. International Journal of Molecular Sciences, 25:10782, Oct 2024. URL: https://doi.org/10.3390/ijms251910782, doi:10.3390/ijms251910782. This article has 3 citations.

19. (jha2023molecularandclinical pages 1-2): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.

20. (english2024geneticsofhereditary pages 1-2): Katherine A. English, Kate E. Lines, and Rajesh V. Thakker. Genetics of hereditary forms of primary hyperparathyroidism. Hormones (Athens, Greece), 23:3-14, Dec 2024. URL: https://doi.org/10.1007/s42000-023-00508-9, doi:10.1007/s42000-023-00508-9. This article has 41 citations.

21. (jha2023molecularandclinical pages 15-16): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.

22. (jha2023molecularandclinical pages 23-24): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.

23. (qadir2024moleculargeneticsin pages 1-3): Ajaz Qadir, Raiz Ahmad Misgar, Ankit Chhabra, Imtiyaz Ahmad Bhat, Mir Iftikhar Bashir, Arshad Iqbal Wani, Munir Ahmad Wani, and Ajaz Ahmad Malik. Molecular genetics in familial primary hyperparathyroidism: a study from northern india. Nov 2024. URL: https://doi.org/10.21203/rs.3.rs-5299691/v1, doi:10.21203/rs.3.rs-5299691/v1.

24. (roser2023diagnosisandmanagement pages 3-5): Pia Roser, Bianca M Leca, Claudia Coelho, Klaus-Martin Schulte, Jackie Gilbert, Eftychia E Drakou, Christos Kosmas, Ling Ling Chuah, Husam Wassati, Alexander D Miras, James Crane, Simon J B Aylwin, Ashley B Grossman, and Georgios K Dimitriadis. Diagnosis and management of parathyroid carcinoma: a state-of-the-art review. Endocrine-Related Cancer, Apr 2023. URL: https://doi.org/10.1530/erc-22-0287, doi:10.1530/erc-22-0287. This article has 80 citations and is from a domain leading peer-reviewed journal.

25. (roser2023diagnosisandmanagement pages 7-8): Pia Roser, Bianca M Leca, Claudia Coelho, Klaus-Martin Schulte, Jackie Gilbert, Eftychia E Drakou, Christos Kosmas, Ling Ling Chuah, Husam Wassati, Alexander D Miras, James Crane, Simon J B Aylwin, Ashley B Grossman, and Georgios K Dimitriadis. Diagnosis and management of parathyroid carcinoma: a state-of-the-art review. Endocrine-Related Cancer, Apr 2023. URL: https://doi.org/10.1530/erc-22-0287, doi:10.1530/erc-22-0287. This article has 80 citations and is from a domain leading peer-reviewed journal.

26. (simonds2020clinicalandmolecular pages 3-4): William F. Simonds. Clinical and molecular genetics of primary hyperparathyroidism. Hormone and Metabolic Research, 52:578-587, Mar 2020. URL: https://doi.org/10.1055/a-1132-6223, doi:10.1055/a-1132-6223. This article has 12 citations and is from a peer-reviewed journal.

27. (simonds2020clinicalandmolecular pages 4-6): William F. Simonds. Clinical and molecular genetics of primary hyperparathyroidism. Hormone and Metabolic Research, 52:578-587, Mar 2020. URL: https://doi.org/10.1055/a-1132-6223, doi:10.1055/a-1132-6223. This article has 12 citations and is from a peer-reviewed journal.

28. (qadir2024moleculargeneticsin pages 9-11): Ajaz Qadir, Raiz Ahmad Misgar, Ankit Chhabra, Imtiyaz Ahmad Bhat, Mir Iftikhar Bashir, Arshad Iqbal Wani, Munir Ahmad Wani, and Ajaz Ahmad Malik. Molecular genetics in familial primary hyperparathyroidism: a study from northern india. Nov 2024. URL: https://doi.org/10.21203/rs.3.rs-5299691/v1, doi:10.21203/rs.3.rs-5299691/v1.

29. (jha2023molecularandclinical pages 11-12): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.

30. (verdelli2024heterogeneoustranscriptionallandscapes pages 7-9): Chiara Verdelli, Silvia Carrara, Riccardo Maggiore, Paolo Dalino Ciaramella, and Sabrina Corbetta. Heterogeneous transcriptional landscapes in human sporadic parathyroid gland tumors. International Journal of Molecular Sciences, 25:10782, Oct 2024. URL: https://doi.org/10.3390/ijms251910782, doi:10.3390/ijms251910782. This article has 3 citations.

31. (costea2025tertiaryhyperparathyroidismin pages 2-4): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.

32. (simonds2020clinicalandmolecular pages 1-3): William F. Simonds. Clinical and molecular genetics of primary hyperparathyroidism. Hormone and Metabolic Research, 52:578-587, Mar 2020. URL: https://doi.org/10.1055/a-1132-6223, doi:10.1055/a-1132-6223. This article has 12 citations and is from a peer-reviewed journal.

33. (sevva2024pharmaceuticalmanagementof pages 2-3): Christina Sevva, Dimitrios Divanis, Ariti Tsinari, Petros Grammenos, Styliani Laskou, Stylianos Mantalobas, Eleni Paschou, Vasiliki Magra, Periklis Kopsidas, Isaak Kesisoglou, Vassilios Liakopoulos, and Konstantinos Sapalidis. Pharmaceutical management of secondary hyperparathyroidism and the role of surgery: a 5-year retrospective study. Medicina, 60:812, May 2024. URL: https://doi.org/10.3390/medicina60050812, doi:10.3390/medicina60050812. This article has 3 citations.

34. (jha2023molecularandclinical pages 10-11): S. Jha and W. Simonds. Molecular and clinical spectrum of primary hyperparathyroidism. Endocrine reviews, Mar 2023. URL: https://doi.org/10.1210/endrev/bnad009, doi:10.1210/endrev/bnad009. This article has 68 citations and is from a domain leading peer-reviewed journal.

35. (chakrabarty2024imagingrecommendationsfor media a62b0df1): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.

36. (scheepers2023diagnosticperformanceof pages 14-15): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.

37. (chakrabarty2024imagingrecommendationsfor pages 9-11): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.

38. (scheepers2023diagnosticperformanceof pages 9-11): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.

39. (scheepers2023diagnosticperformanceof pages 1-2): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.

40. (scheepers2023diagnosticperformanceof pages 2-4): Max H. M. C. Scheepers, Zaid Al-Difaie, Lloyd Brandts, Andrea Peeters, Bjorn Winkens, Mahdi Al-Taher, Sanne M. E. Engelen, Tim Lubbers, Bas Havekes, Nicole D. Bouvy, and Alida A. Postma. Diagnostic performance of magnetic resonance imaging for parathyroid localization of primary hyperparathyroidism: a systematic review. Diagnostics, 14:25, Dec 2023. URL: https://doi.org/10.3390/diagnostics14010025, doi:10.3390/diagnostics14010025. This article has 10 citations.

41. (costea2025tertiaryhyperparathyroidismin pages 10-12): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.

42. (chakrabarty2024imagingrecommendationsfor media 9629bfff): Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D’Cruz. Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review. Cancers, 16:2593, Jul 2024. URL: https://doi.org/10.3390/cancers16142593, doi:10.3390/cancers16142593. This article has 25 citations.

43. (NCT03027557 chunk 2): Peter Vestergaard. Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.. Peter Vestergaard. 2017. ClinicalTrials.gov Identifier: NCT03027557

44. (costea2025tertiaryhyperparathyroidismin pages 9-10): Mirona Costea, D. Tilici, D. Păun, V. Nimigean, S. Paun, and R. Dǎnciulescu-Miulescu. Tertiary hyperparathyroidism in diabetic nephropathy: an underrecognized complication—a narrative review. Biomedicines, Oct 2025. URL: https://doi.org/10.3390/biomedicines13112604, doi:10.3390/biomedicines13112604. This article has 2 citations.

45. (vetter2024whatisthe pages 17-18): Diana Vetter and Thomas Schachtner. What is the role of surgery in secondary and tertiary hyperparathyroidism? Advances in Kidney Transplantation [Working Title], Aug 2024. URL: https://doi.org/10.5772/intechopen.1006528, doi:10.5772/intechopen.1006528. This article has 0 citations.

46. (sevva2024pharmaceuticalmanagementof pages 1-2): Christina Sevva, Dimitrios Divanis, Ariti Tsinari, Petros Grammenos, Styliani Laskou, Stylianos Mantalobas, Eleni Paschou, Vasiliki Magra, Periklis Kopsidas, Isaak Kesisoglou, Vassilios Liakopoulos, and Konstantinos Sapalidis. Pharmaceutical management of secondary hyperparathyroidism and the role of surgery: a 5-year retrospective study. Medicina, 60:812, May 2024. URL: https://doi.org/10.3390/medicina60050812, doi:10.3390/medicina60050812. This article has 3 citations.